52-Week Performance Chart

Powered by FactSet Research Systems Inc

Corporate Actions/Books Closed

Institutional Ownership

TOP INSTITUTIONAL HOLDERS POSITION
TOP MUTUAL FUND HOLDERS POSITION

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol SPHRY
CUSIP 855563102
DR Venue OTC
DR ISIN US8555631022
Ratio DR:ORD 1:10
Underlying ISIN AU000000SPL0
Underlying SEDOL 6291596
Country Australia
Effective Date Dec 29, 2004
Depositary BK (Sponsored)
Industry Pharma. & Biotech.
Books Open/Closed Open
Starpharma Holdings engaged in research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. Activities within the Company is directed towards the development of precisely defined nanoparticles called dendrimers, including on the development of VivaGel® for the management and prevention of bacterial vaginosis, and as a condom coating. The Company is also applying its proprietary dendrimers to drug delivery. The Company's Dendrimer Enhanced Product technology (DEP (TM)) consists of: DEP® docetaxel, which is used for pancreatic cancer; DEP® cabazitaxel, which is used for prostate and ovarian cancer; and DEP® irinotecan, which is used for colon cancer.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Annual Depositary Service up to $0.0500
Cancellation up to $0.0500
Cash Distribution up to $0.0500
Issuance up to $0.0500
Registrar Inspection up to $0.0000
Cash Distribution(Other) up to $0.0500
Rights - Issuance up to $0.0500
Stock Dividend up to $0.0500
Transfer up to $0.0000
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
May.25 0.56 10,927 1,366
Apr.25 0.60 16,479 2,060
Mar.25 0.59 4,350 1,450

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE